journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology Research and Practice

journal
https://www.readbyqxmd.com/read/28174665/metastatic-small-cell-neuroendocrine-carcinoma-of-the-cervix-treated-with-the-pd-1-inhibitor-nivolumab-a-case-report
#1
Sarah E Paraghamian, Teresa C Longoria, Ramez N Eskander
BACKGROUND: Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. CASE PRESENTATION: We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28138393/clinical-features-and-treatment-of-vulvar-merkel-cell-carcinoma-a-systematic-review
#2
REVIEW
Austin Huy Nguyen, Ahmed I Tahseen, Adam M Vaudreuil, Gabriel C Caponetti, Christopher J Huerter
BACKGROUND: Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently available literature primarily in case report form. BODY: Systematic review of the PubMed database returned 17 cases of Merkel cell carcinoma affecting the vulva. Patients presented at a mean age of 59.6 years with a firm, mobile vulvar mass. Symptoms of pain, erythema, pruritus, edema, and ulceration have been reported...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28116108/disparities-in-the-surgical-staging-of-high-grade-endometrial-cancer-in-the-united-states
#3
Jonathan R Foote, Stephanie Gaillard, Gloria Broadwater, Julie A Sosa, Brittany Davidson, Mohamed A Adam, Angeles Alvarez Secord, Monica B Jones, Junzo Chino, Laura J Havrilesky
BACKGROUND: The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. Our goal was to examine surgical staging patterns for high-grade endometrial cancer in the United States. METHODS: The National Cancer Data Base (NCDB) was searched for patients who underwent surgery for serous, clear cell, or grade 3 endometrioid endometrial cancer...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27999680/new-classification-of-endometrial-cancers-the-development-and-potential-applications-of-genomic-based-classification-in-research-and-clinical-care
#4
REVIEW
A Talhouk, J N McAlpine
Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distinguish these tumors and enable a subtype-specific approach to research and clinical care. Based on the Cancer Genome Atlas, two research teams have developed pragmatic molecular classifiers that identify four prognostically distinct molecular subgroups. These methods can be applied to diagnostic specimens (e...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27980799/analysis-of-in-vitro-chemoresponse-assays-in-endometrioid-endometrial-adenocarcinoma-an-observational-ancillary-analysis
#5
Brittany A Davidson, Jonathan Foote, Stacey L Brower, Chunqiao Tian, Laura J Havrilesky, Angeles Alvarez Secord
BACKGROUND: Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemoresponse. METHODS: We conducted an analysis of primary tumor samples from women with EEC undergoing in vitro chemoresponse testing. Results were classified as sensitive (S), intermediate (I), or resistant (R) to each drug tested. Correlations between tumor grade and response were examined...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27980798/genetic-testing-in-a-gynaecological-oncology-care-in-developing-countries-knowledge-attitudes-and-perception-of-nepalese-clinicians
#6
Hanoon P Pokharel, Neville F Hacker, Lesley Andrews
BACKGROUND: Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice. Little information is currently available about physicians' attitudes towards these tests in developing countries. METHODS: We conducted an email survey of Nepalese physicians practicing in academic and non-academic settings in Nepal, regarding knowledge, attitudes and perception towards genetic testing for gynaecologic cancer. RESULTS: Responses were received from 251 of 387 practitioners (65%)...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27904752/the-role-of-immune-checkpoint-inhibition-in-the-treatment-of-ovarian-cancer
#7
REVIEW
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with objective response rates of 10-15% with some durable responses. In this review, we present emerging clinical data of completed trials of immune checkpoint inhibitors and review ongoing studies. In addition we examine the current knowledge of the tumor microenvironment of ovarian cancers with a focus on the significance of PD-L1 expression and tumor-infiltrating lymphocytes on predicting response to immune checkpoint blockade...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27795832/fertility-sparing-management-in-cervical-cancer-balancing-oncologic-outcomes-with-reproductive-success
#8
REVIEW
Karla Willows, Genevieve Lennox, Allan Covens
BACKGROUND: Cervical cancer is the fourth most common cancer among women worldwide, many of who are still within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for early stage disease to over 90 % in developed countries. The focus is now shifting to reducing morbidity and improving fertility outcomes for cervical cancer patients. Radical trachelectomy with lymph node assessment became the standard of care for selected women with lesions <2 cm who desire fertility preservation...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27468354/fertility-preservation-in-women-with-cervical-endometrial-or-ovarian-cancers
#9
REVIEW
Michael Feichtinger, Kenny A Rodriguez-Wallberg
BACKGROUND: Although cancer in general affects an aged population, a significant number of women develop cancer at childbearing age. Long-term survival rates after gynecological cancer, especially in young patients are increasing and all quality-of-life aspects, including preservation of fertility have become of major relevance. OUTCOMES: Surgical techniques aimed at sparing reproductive organs and preserving fertility have been developed for women presenting with gynecological cancer found at early stages...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27408749/long-term-follow-up-of-a-phase-ii-trial-of-multimodal-therapy-given-in-a-sandwich-method-for-stage-iii-iv-and-recurrent-endometrial-cancer
#10
Michelle Glasgow, Rachel Isaksson Vogel, Jennifer Burgart, Peter Argenta, Kathryn Dusenbery, Melissa A Geller
BACKGROUND: Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy. METHODS: Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27330821/surgical-management-of-lung-liver-and-brain-metastases-from-gynecological-cancers-a-literature-review
#11
REVIEW
Neville F Hacker, Archana Rao
BACKGROUND: The management of patients with recurrent gynecological malignancy is complex, and often contentious. While historically, patients with metastases in the lungs, liver or brain have been treated with palliative intent, surgery is proving to have an increasing role in the management of such patients. METHODS: In this review article, the surgical management of lung, liver and brain metastases from gynecological cancers is examined. A search of the English language literature over the last 25 years was conducted using the Medline and PubMed databases...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27232495/erratum-to-immunotherapy-in-endometrial-cancer-an-evolving-therapeutic-paradigm
#12
Teresa C Longoria, Ramez N Eskander
[This corrects the article DOI: 10.1186/s40661-015-0020-3.].
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231576/a-long-term-surviving-patient-with-recurrent-low-grade-serous-ovarian-carcinoma-treated-with-the-mek1-2-inhibitor-selumetinib
#13
Munetaka Takekuma, Kwong K Wong, Robert L Coleman
BACKGROUND: Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of solid tumor including recurrent low-grade serous ovarian carcinoma (LGSOC). However, the long-term prognosis of patients who receive selumetinib, as well as the late toxicity of the agent, have not yet been described. CASE PRESENTATION: In this case report, we present a patient with recurrent LGSOC with KRAS mutation whose tumor has not progressed and who has maintained a good general condition without severe toxicities following treatment with selumetinib for more than 7 years...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231575/safety-and-efficacy-of-salvage-nano-particle-albumin-bound-paclitaxel-in-recurrent-cervical-cancer-a-feasibility-study
#14
Lindsey E Minion, Dana M Chase, John H Farley, Lyndsay J Willmott, Bradley J Monk
BACKGROUND: After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treating recurrent, refractory cervical cancer with nano-particle albumin bound (NAB) paclitaxel with or without bevacizumab. METHODS: This retrospective case series was conducted in accordance with the regulations set forth by the Institutional Review Board at St...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231574/new-treatment-option-for-ovarian-cancer-parp-inhibitors
#15
REVIEW
Robert S Meehan, Alice P Chen
Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (ssDNA) and then effecting DNA repair. A double-strand DNA (dsDNA) break can be repaired by one of two different pathways: homologous recombination (HR) or non-homologous end joining (NHEJ). Homologous recombination occurs in the G2 or M phase of the cell cycle when a sister chromatid is available to use as a template for repair...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231573/surgical-safety-and-personal-costs-in-morbidly-obese-multimorbid-patients-diagnosed-with-early-stage-endometrial-cancer-having-a-hysterectomy
#16
Andreas Obermair, Donal J Brennan, Eva Baxter, Jane E Armes, Val Gebski, Monika Janda
BACKGROUND: Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-surgical treatment to these women, but not all may agree to participate in such trials. This paper aims to describe the patient characteristics, and surgical outcomes of women with suspected early stage endometrial cancer and body mass index (BMI) of 30 or greater, who declined enrolment in the feMMe trial, which offers non-surgical hormonal treatment, hormonal plus metformin or hormonal plus weight loss as primary treatment...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231572/lumbosacral-plexopathy-a-rare-long-term-complication-of-concomitant-chemo-radiation-for-cervical-cancer
#17
Imane Bourhafour, Meriem Benoulaid, Hanane El Kacemi, Sanae El Majjaoui, Tayeb Kebdani, Noureddine Benjaafar
Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer survival. This entity commonly results in different degrees of sensory and motor deficits. The pathophysiological mechanisms are not yet fully understood. Diagnosis of radiation myelopathy in women with gynecologic malignancies may increase with the use of concomitant chemo-radiation. This report describes the effect of this combination therapy in a 64-year-old woman with cervical carcinoma...
2015: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231571/immunotherapy-in-endometrial-cancer-an-evolving-therapeutic-paradigm
#18
REVIEW
Teresa C Longoria, Ramez N Eskander
Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease is confined to the uterus, patients with metastatic or recurrent disease exhibit limited response rates to cytotoxic chemotherapy, targeted agents, or hormonal therapy. Given the unmet clinical need in this patient population, exploration of novel therapeutic approaches is warranted, and attention is turning to immunomodulation of the tumor microenvironment...
2015: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231570/characteristics-and-outcomes-for-patients-with-advanced-vaginal-or-vulvar-cancer-referred-to-a-phase-i-clinical-trials-program-the-md-anderson-cancer-center-experience
#19
Siqing Fu, Naiyi Shi, Jennifer Wheler, Aung Naing, Filip Janku, Sarina Piha-Paul, Jing Gong, David Hong, Apostolia Tsimberidou, Ralph Zinner, Vivek Subbiah, Ming-Mo Hou, Pedro Ramirez, Lois Ramondetta, Karen Lu, Funda Meric-Bernstam
BACKGROUND: Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required. METHODS: In this retrospective study, we analyzed the clinical outcomes of consecutive patients with metastatic vaginal or vulvar cancer who were referred to a phase I trial clinic between January 2006 and December 2013. Demographic and clinical data were obtained from patients' electronic medical records...
2015: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27231569/clinico-epidemiological-profile-of-molar-pregnancies-in-a-tertiary-care-centre-of-eastern-nepal-a-retrospective-review-of-medical-records
#20
Nimisha Agrawal, Reshu Agrawal Sagtani, Shyam Sundar Budhathoki, Hanoon P Pokharel
BACKGROUND: The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine prevalence of molar pregnancies and demonstrate clinical and epidemiological characteristics of the patients attending a tertiary care center in eastern Nepal. METHODS: A retrospective review of medical records was conducted to determine the prevalence of molar pregnancies at the B...
2015: Gynecologic Oncology Research and Practice
journal
journal
53287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"